Participant with Rectal Adenocarcinoma for Rectal Adenocarcinoma

Phase-Based Progress Estimates
Memorial Sloan Kettering Cancer Center - All Protocol Activities, New York, NYRectal Adenocarcinoma+4 MoreTrastuzumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial suggests a combo of trastuzumab/tucatinib with chemo may help treat rectal cancer.

Eligible Conditions
  • Rectal Adenocarcinoma
  • Locally Advanced Rectal Cancer
  • Rectal Cancer
  • HER2 Positive Rectal Adenocarcinoma
  • Colorectal Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 21 +/- 4 weeks

21 +/- 4 weeks
Clinical complete response of study participants

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Participant with Rectal Adenocarcinoma
1 of 1

Experimental Treatment

37 Total Participants · 1 Treatment Group

Primary Treatment: Participant with Rectal Adenocarcinoma · No Placebo Group · Phase 2

Participant with Rectal AdenocarcinomaExperimental Group · 2 Interventions: Trastuzumab, Tucatinib · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Completed Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 21 +/- 4 weeks

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,846 Previous Clinical Trials
590,031 Total Patients Enrolled
1 Trials studying Rectal Adenocarcinoma
200 Patients Enrolled for Rectal Adenocarcinoma
Andrea Cercek, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer
9 Previous Clinical Trials
1,349 Total Patients Enrolled
1 Trials studying Rectal Adenocarcinoma
200 Patients Enrolled for Rectal Adenocarcinoma

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Can you explain the safety level of those involved in the Participant with Rectal Adenocarcinoma study?

"The safety of those with rectal adenocarcinoma was assessed as a 2 due to the existent data supporting its security, yet lacking evidence for efficacy in this Phase 2 trial." - Anonymous Online Contributor

Unverified Answer

Are there opportunities for individuals to register at present for this clinical experiment?

"Affirmative, according to data found on this medical trial is currently open for enrollment and was originally posted December 30th 2022. Last updated January 3rd 2023, the study seeks to recruit 37 patients from 7 distinct sites." - Anonymous Online Contributor

Unverified Answer

Are there numerous locations in Canada where this research is being conducted?

"This clinical trial is presently open at 7 sites, including Middletown, Montvale and Commack. To reduce the burden of travelling to these locations, it is prudent for potential participants to select a site in close proximity to them." - Anonymous Online Contributor

Unverified Answer

How many people can partake in this experiment?

"Indeed, according to, this investigation is actively open for enrollment. This trial was initially published on December 30th 2022 and last edited on January 3rd 2023; it seeks 37 patients from 7 eligible sites." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.